SCHEMBL29988822

SCHEMBL29988822

O=C(c1cc2ccccc2[nH]1)C12CC3CC(CC(C3)C1)C2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.65
FLT3 P36888 5/20 0.54
KDM4E B2RXH2 3/20 0.53
MAPT P10636 1/20 0.53
DAO P14920 1/20 0.53
HPGD P15428 1/20 0.53
SRD5A2 P31213 1/20 0.53
HSD17B10 Q99714 1/20 0.53
PTPN2 P17706 1/20 0.48
PTPN1 P18031 1/20 0.48
ALDH1A1 P00352 1/20 0.48
GAA P10253 1/20 0.48
MAPK1 P28482 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
LMNA P02545 3/20 0.47
NPC1 O15118 2/20 0.47
RAB9A P51151 2/20 0.47
HTT P42858 1/20 0.47
MAOB P27338 1/20 0.46
HRH4 Q9H3N8 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5507378 0.83 FLT3 (0.56) CNR2FLT3MAPTGAAHRH4
SCHEMBL5510077 0.82 KDM4E (0.56) CNR2FLT3KDM4EDAOHPGD
SCHEMBL5508886 0.82 FLT3 (0.48) CNR2FLT3KDM4EDAOHPGD
SCHEMBL5507170 0.80 PDGFRB (0.62) FLT3KDM4EHPGDALDH1A1LMNA
SCHEMBL19837639 0.79 CNR2 (1.00) CNR2FLT3KDM4EMAPTHPGD
SCHEMBL5505370 0.79 CNR2 (0.43) CNR2KDM4EHSD17B10ALDH1A1MAPK1
SCHEMBL5508084 0.78 KDM4E (0.66) CNR2FLT3KDM4EMAPTHPGD
SCHEMBL19837646 0.76 CNR2 (0.67) CNR2KDM4EHPGDHSD17B10ALDH1A1
SCHEMBL19837641 0.74 CNR2 (0.65) CNR2KDM4EHPGDALDH1A1GAA
SCHEMBL27573152 0.72 CNR2 (0.66) CNR2KDM4EMAPTHSD17B10MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022217147-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES ROSENFELD MARK J (US) 2022-10-13 WO claimed
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES Ananda Scientific, Inc. (US) 2025-06-19 US disclosed
WO-2022217147-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES ROSENFELD MARK J (US) 2022-10-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250195409-A1 METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES CNR2, CNR1, FAAH CNR2 1/4885FLT3 2997/4885KDM4E 1623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.